Surgery Partners Soars 48% on $5.7B Buyout: Time to Sell?

Surgery Partners (SGRY) stock skyrocketed 47.62% on October 26, closing at $23.25, after the company agreed to be acquired by HealthSpan Partners, an affiliate of Bon Secours Mercy Health, for $5.7 billion in cash. The deal values each SGRY share at $23.50, a slight premium to the closing price. Trading volume exploded to 58.3 million shares, about 1,772% above its three-month average, as investors rushed to capitalize on the news.

The acquisition is structured as an all-cash take-private transaction, meaning SGRY will no longer be publicly traded once completed. The deal is expected to close in the first quarter of 2027, subject to regulatory approvals and shareholder vote. Notably, Bain Capital, which owns roughly 39% of SGRY, has already agreed to vote in favor, significantly increasing the likelihood of approval.

Surgery Partners went public in 2015 and has grown 22% since its IPO, but the buyout price of $23.50 is roughly where the stock traded a year ago. That suggests HealthSpan is getting a relative bargain, especially considering the company's long-term growth potential in the outpatient surgery market.

Broader markets were up modestly on the day, with the S&P 500 gaining 0.70% and the Nasdaq Composite rising 0.82%. Peer outpatient surgery companies had mixed reactions: Tenet Healthcare (THC) edged up 0.18%, while HCA Healthcare (HCA) slipped 0.91%, indicating that the acquisition is seen as a company-specific event rather than a sector-wide catalyst.

For current SGRY shareholders, the 48% pop is a windfall, but the stock now trades less than 1% below the $23.50 acquisition price. That tiny spread implies the market is highly confident the deal will close, leaving minimal upside from here. The real question is whether to lock in gains now or wait until the deal finalizes in early 2027 to capture the remaining $0.25 per share.

Given the lengthy timeline, holding SGRY until 2027 ties up your capital for over a year with little potential return. The annualized yield on that remaining spread is less than 1%, which is far below what you could earn in a savings account or short-term Treasury. Moreover, there's always a small risk that regulatory hurdles or unforeseen events could derail the deal, causing the stock to plummet.

The acquisition also highlights the ongoing consolidation in the healthcare sector, particularly in outpatient surgery centers. HealthSpan's willingness to pay a premium for SGRY, despite the stock being at a one-year low, signals that strategic buyers see value in these assets. This could prompt other players to consider similar moves, though peers like THC and HCA showed little reaction today.

For investors in the broader healthcare space, this deal reinforces the importance of outpatient services as a growth area. However, it's unlikely to trigger a wave of buyouts across the sector, as each company's situation is unique. The muted response from THC and HCA suggests that the market views this as a one-off event.

Ultimately, the SGRY buyout is a reminder that merger arbitrage can offer quick gains but limited upside once the initial pop occurs. Investors should weigh the opportunity cost of holding a stock with a fixed payout against other investments with better return potential.